Tobacco Leaf, Smoke and Smoking, MAO Inhibitors, Parkinson's Disease and Neuroprotection; Are There Links?

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 279-291

  Castagnoli, Kay ^a   Murugesan, Thangaraju ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

MAO inhibitors; Neuroprotection; Parkinson's disease; Smoking; Tobacco leaf

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 NAPHTHYLAMINE; 2,3 DIHYDRO 1 METHYL 4 PHENYLPYRIDINIUM; 7 NITROINDAZOLE; AMINE OXIDASE (FLAVIN CONTAINING); CLORGYLINE; COTININE; DOPAMINE; HYDRAZINE; MONOAMINE OXIDASE INHIBITOR; NAPHTHOQUINONE; NEUROTOXIN; NICOTINE; PHENETHYLAMINE; RASAGILINE; SELEGILINE; SEROTONIN; THIOCYANATE; TOBACCO SMOKE; TYRAMINE;

BRAIN; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SMOKING; THROMBOCYTE; TOBACCO;

GYMNOMYZA SAMOENSIS; NICOTIANA TABACUM; PARKINSONIA;

EID: 0347415715     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00107-4     Document Type: Article

References (105)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991;337:1321-4.
2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326:105-8.
3. Behmand RA, Harik SI. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 1992;58:776-9.
4. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B in activities in heavy smokers. Biol Psychiatry 1995;38:756-61.
5. Berlin I, Said S, Spreux-Varoquaux O, Launay JM. Platelet MAOB activity inversely associated with plasma cotinine concentration. Nicotine Tob Res 2000;2:243-6.
6. Burch PRJ. Cigarette smoking and Parkinson's disease. Neurology 1981;31:500-3.
7. Carr LA, Rowell PP. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology 1990;29:311-4.
8. Carr LA, Basham JK. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci 1991;48:1173-7.
9. Castagnoli N, Chiba K, Trevor AJ. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP). Life Sci 1985;36:225-30.
10. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase B catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 1997;10:364-8.
11. Castagnoli K, Palmer S, Castagnoli N. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity. Neurobiology 1999;7:135-49.
12. Castagnoli K, Steyn SJ, Petzer JP, Van der Schyf CJ, Castagnoli N. Neuroprotection in the MPTP parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chem Res Toxicol 2001;14:523-7.
13. Castagnoli K, Steyn S, Magnin G, Van der Schyf CJ, Fourie I, Khalil A et al. Studies on the interaction of tobacco leaf and tobacco smoke constituents and monoamine oxidase. Neurotoxicity Res 2002;4:51-8.
14. Castagnoli N, Fourie I, Van der Schyf CJ. Smoke extracts and their MAO inhibiting properties, 2003a, in preparation.
15. Castagnoli K, Murugesan T, Fourie I, Van der Schyf CJ, Castagnoli N. The effects on rat brain MAO activity following long term exposure to cigarette smoke extracts, 2003b, in preparation.
16. Chamberlain WJ, Stedman RL. Composition studies on tobacco. XXVIII. 2,3,6-Trimethyl-1,4-naphthoquinone in cigarette smoke. Phytochemistry 1968;7:309-16.
17. Chiba K, Trevor AJ, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-8.
18. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 1985;13:342-7.
19. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Richert CM et al. Chronic parkinsonism secondary in intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-54.
20. Di Monte DA, Wu EY, Irwin I, DeLanney LE, Langston JW. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. J Pharmacol Exp Ther 1991;258:594-600.
21. Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagnoli N, Langston JW. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 1997;69:1771-3.
22. Duvoisin RC, Golbe LI. Kindreds of dominantly inherited Parkinson's disease: keys to the riddle. Ann Neurol 1995;38:355-66.
23. Elbaz A, Manubens-Bertran JM, Baldereshi M, Breteler MMB, Grigoletto F, Lopez-Pousa S et al. Parkinson's disease, smoking, and family history. J Neurol 2000;247:793-8.
24. Essman WB. Serotonin and monoamine oxidase in mouse skin: effects of cigarette smoke exposure. J Med 1977;8:95-101.
25. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K. Effects of nicotine on hydroxy free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 1998;358:351-9.
26. Finberg JPM, Lamensdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm 1996;48:95-103.
27. Flaherty P, Castagnoli K, Wang YX, Castagnoli N. Synthesis and selective monoamine oxidase B-inhibiting properties of 1-methyl-1,2,3,6-tetrahydropyrid-4-yl-carbamate derivatives: potential prodrugs of (R)-and (S)-nordeprenyl. J Med Chem 1996;39:4756-61.
28. Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235:481-5.
29. Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor R et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995;36:1255-62.
30. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996a;379:733-6.
31. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C et al. Brain monoamine oxidase inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996b;93:14065-9.
32. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R et al. Neuropharmacological action of cigarette smoke brain monoamine oxidase B (MAOB) inhibition. J Addict Disord 1998a;17:23-34.
33. Fowler JS, Volkow ND, Logan J, Pappas N, King P, MacGregor R et al. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci 1998b;63:19-23.
34. Fowler JS, Wang GJ, Volkow ND, Franceschi D, Logan J, Pappas N et al. Maintenance of brain monoamine oxidase B inhibition in smokers after an overnight cigarette abstinence. Am J Psychiatry 2000;1:325-9.
35. Fuller RW, Hemrick-Luecke SK. Deprenyl protection against striatal dopamine depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Res Commun Subst Abuse 1984;5:241-6.
36. Fuller RW, Hemrick-Luecke SK. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Life Sci 1985;37:1089-96.
37. Fung YK, Fiske LA, Lau YS. Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. Gen Pharmacol 1991;22:669-72.
38. Gao SG, Cui WY, Shang HT, Liu CG. Effects of nicotine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacol Res 1998;38:101-6.
39. Giroud M, Vincent MC, Thierry A, Binnert D, Marin A, Dumas R. Parkinsonian syndrome caused by traumatic hematomas in the basal ganglia. Neuro-Chirurgie 1988;34:61-3.
40. Golbe LI, Di Iorio G, Sanges G, Lazzarini AM, La Sala S, Bonavita V et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-75.
41. Gorrell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999;52:115-9.
42. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-38.
43. Guterman A, Smith RW. Neurological sequelae of boxing. Sports Med 1987;4:194-210.
44. Hadjidonstantinou M, Hubble JP, Wemlinger TA, Neff NH. Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonist. J Pharmacol Exp Ther 1994;270:639-44.
45. Hauptman N, Shih JC. 2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci 2001;68:1231-41.
46. Heikkila RE. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur J Pharmacol 1985;117:131-3.
47. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-9.
48. Hoskins JA, Davis LJ. The acute effect on levels of catecholamines and metabolites in brain of a single dose of MPTP in 8 strains of mice. Neuropharmacology 1989;28:1389-97.
49. Inoue H, Castagnoli K, Van der Schyf C, Mabic S, Igarashi K, Castagnoli N. Species dependent differences in the monoamine oxidase A and B catalyzed oxidation of various C-4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 1999;292:856-64.
50. Jacob III, P, Ulgen M, Gorrod JW. Metabolism of (-)-(S)-nicotine by guinea pig and rat brain: identification of cotinine. Eur J Drug Metab Pharmacokinet 1997;22:391-4.
51. Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988;132:589-91.
52. Janson AM, Fuxe K, Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest 1992;70:232-8.
53. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: up take of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-7.
54. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
55. Jossan SS, Sakurai E, Oreland L. Is the monoamine oxidase B activity rate limiting for MPTP neurotoxicity? Biogenic Amines 1987;4:371-9.
56. Khalil AA, Steyn S, Castagnoli N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 2000;13:31-5.
57. Kimland B, Appleton AJ, Aasen AJ, Roseraade J, Enzell CR. Neutral oxygen-containing volatile constituents of Greek tobacco. Phytochemistry 1972;11:309-16.
58. Knoll J, Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem PsychoPharmacol 1972;5:393-408.
59. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1988;18:106-8.
60. Langston JW. Parkinson's disease: current and future challenges. NeuroToxicology 2002;23:443-50.
61. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
62. Langston JW, Irwin I, Langston EB, Forno LS. 1-Methyl-4-phenyl-pyridinium ion (MPP+): identification of metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984;48:87-92.
63. Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982;79:6385-9.
64. Lousie N, Michel P, Joseph Z. Manganese neurotoxicity: behavioral pathological and biochemical effects following various routes of exposure. Rev Environ Health 2002;17:189-217.
65. Maggio R, Riva M, Vaglini F, Fornai F, Racagni G, Corsini GU. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J Neural Transm 1997;104:1113-23.
66. Magyar K, Szende B, Langyel J, Tarczali J, Szatmary I. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl 1998;52:109-23.
67. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-7.
68. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-51.
69. Norman TR, Chamberlain KG, French MA, Burrows GD. Platelet monoamine oxidase activity and cigarette smoking. J Affect Disord 1982;4:73-7.
70. Norman TR, Chamberlain KG, French MA. Platelet monoamine oxidase: low activity in cigarette smokers. Psychiatry Res 1987;20:199-205.
71. Oreland L, Fowler CJ, Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 1981;29:2511-8.
72. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastsopoulos I. Mutated α-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999;52:651-4.
73. Parain K, Marchand V, Dumery B, Hirsch E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res 2001;890:347-50.
74. Parkinson J. An essay on the shaking palsy. London: Neely and Jones; 1817.
75. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
76. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's disease: evidence for a single etiology related to sub-clinical infection about 1920. J Chronic Dis 1963;16:961-73.
77. Propping P, Ray ER, Friedl W, Beckman H. Platelet monoamine oxidase in healthy subjects: the 'biochemical high-risk paradigm' revisited. Arch Psychiatry Nervenkr 1981;230:209-19.
78. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double blind study as adjunctive therapy of levodopa. Clin NeuroPharmacol 2000;23:324-30.
79. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 1991;56:1184-90.
80. +. Neurosci Lett 1987;75:323-8.
81. Riachi NJ, Harik SI, Kalaria RN, Sayre LM. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. 11. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain mocrovessels and liver. J Pharmacol Exp Ther 1988;244:443-8.
82. Royland JE, Langston JW. MPTP: a dopaminergic neurotoxin. In: Kostrzewa RM, editor. Highly selective neurotoxins: basic and clinical applications. Totowa, NJ, USA: Humana Press; 1998. p. 141-94.
83. Saccone NL, Rice JP, Rochberg N, Goate A, Reich T, Shears S et al. Genome screen for platelet monoamine oxidase (MAO) activity. Am J Med Genet (Neuropsychiatric Genet) 1999;88:517-21.
84. + to dopaminergic neurons of the rat substantia nigra. Eur J Pharmacol 1986;124:171-4.
85. Schinelli S, Zuddas A, Kopin IJ, Barker JL, Di Porzio U. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon. J Neurochem 1988;50:1900-7.
86. Sershen H, Mason MR, Reith ME, Hashim A, Lajtha A. Effect of nicotine and amphetamine on the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neuropharmacology 1986;25:1231-4.
87. Sershen H, Hashim A, Lajtha A. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacol Biochem Behav 1987;28:299-303.
88. Sershen H, Hashim A, Wiener HL, Lajtha A. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Neurosci Lett 1988;93:270-4.
89. Shahi GS, Das NP, Moochhala SM. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyrine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment. Neurosci Lett 1991;127(2):247-50.
90. Sherratt AJ, Culpepper BT, Lubawy. Prostacylin and thromboxane formation following chronic exposure to cigarette smoke condensate administered via osmotic pumps in rats. J Pharmacol Methods 1988;20:47-56.
91. Shigenaga M. Studies on the metabolism and bioactivation of (S)-nicotine and beta-nicotyrine. Ph.D. thesis, University of California, San Francisco, CA; 1989. p. 162-6.
92. Shoulson I, Oakes D, Fahn S, Lang A, Langston W, LeWitt P et al. The Parkinson study group. Impact of sustained deprenyl (selegiline) in levadopa treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-12.
93. Simpson GM, Shih JC, Chen K, Flowers C, Kumazawa T, Spring B. Schizophrenia, monoamine oxidase activity, and cigarette smoking. Neuropsychopharmacology 1999;4:392-4.
94. Singer TP, Salach JI, Castagnoli NJ, Trevor AJ. Interactions of the neurotoxic amine toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidase. Biochemistry 1986;235:785-9.
95. Spath E, Kesztler F. Tobacco alkaloids. XIII. New tobacco bases. Ber 1937;70:2450-4.
96. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-35.
97. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R et al. Parkinson's disease in twins: an etiologic study. J Am Med Assoc 1999;281:341-6.
98. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-72.
99. + levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 1996;5:129-36.
100. von Knorring L, Oreland L. Personality traits and platelet MAO in tobacco smokers. Psychol Med 1985;15:327-34.
101. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985;230:181-3.
102. Wu EY, Smith MT, Bellomo G, Di Monte DA. Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Arch Biochem Biophys 1990;282:358-62.
103. Yong VW, Perry TL. Monoamine oxidase B, smoking, and Parkinson's disease. J Neurol Sci 1986;72:265-72.
104. Youngster SK, McKeown KA, Jin YZ, Ramsay RR, Heikkila RE, Singer TP. Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J Neurochem 1989;1837-42.
105. Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987;41:675-82.